arrow
A

Aaron S. Mansfield

Mayo Clinic
H指数:56
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Functional precision genomics identifies transcriptional features of therapeutic response and drug resistance in high-grade gliomas

功能精准基因组学鉴定了治疗反应和药物耐药性在高级别胶质瘤中的转录特征

2026-10-270
OAAI
Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee

胸腺上皮肿瘤的诊断与管理挑战与争议——国际肺癌研究协会罕见肿瘤委员会胸腺肿瘤分委会

2026-04-100
PRE
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support

劳拉替尼(Lorlatinib)与神经认知不良事件:特征、风险因素及社会支持可能具有的缓解作用

2025-11-260
PRE
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用:来自III期PAPILLON研究的治疗交叉和其他终点的影响

2025-11-030
OAAI
DNA-junction-based Personalized Liquid Biopsy Assays could inform management of Aggressive Endometrial Cancer

基于DNA-junction的个性化液体活检检测方法可能有助于指导对Aggressive Endometrial Cancer的管理

2025-11-030
PRE
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

患者报告结局和症状进展时间来自PAPILLON研究:amivantamab联合化疗对比化疗作为表皮生长因子受体(EGFR)外显子20插入突变型晚期非小细胞肺癌的一线治疗

2025-10-030
PRE
The Genomic and Transcriptomic Landscape of Recurrent Small Cell Lung Cancer – Pathway Insights and Stratification for Precision Oncology

复发性小细胞肺癌的基因组学和转录组学景观——通路洞察与精准肿瘤学的分层研究

2025-08-290
PRE
International guidelines on the diagnosis and treatment of NUT carcinoma

NUT癌的诊断与治疗国际指南

2025-07-310
OAAI
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial

血浆置换和放射治疗重新使免疫疗法抵抗性黑色素瘤敏感:一项I期试验

2025-03-130
OA
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer

先天性免疫系统,身体习惯和性别对Anetumab Ravtansine在癌症患者中的药代动力学和药效学的评估

2025-03-010
OAAI